Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hematologic Diseases 1

Interventions

Rituximab 4Tacrolimus 3fludarabine 2cobomarsen 2Peripheral Blood Stem Cell Transplantation 2Ganciclovir 2Etoposide 2Cyclophosphamide 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine phosphate 1ferric carboxymaltose 1epratuzumab 1denileukin diftitox 1dacetuzumab 1beta-Glucans 1arginine butyrate 1Vorinostat 1Vincristine 1Valganciclovir 1Stem Cell Transplantation 1Sirolimus 1Prednisone 1Oxycodone 1Mycophenolic Acid 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoproliferative Disorders × dacetuzumab × Clear all
NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡